Liao, Chen http://orcid.org/0000-0001-8474-1196
Taylor, Bradford P. http://orcid.org/0000-0001-7808-955X
Ceccarani, Camilla
Fontana, Emily
Amoretti, Luigi A.
Wright, Roberta J.
Gomes, Antonio L. C. http://orcid.org/0000-0003-3790-3724
Peled, Jonathan U. http://orcid.org/0000-0002-4029-7625
Taur, Ying
Perales, Miguel-Angel
van den Brink, Marcel R. M.
Littmann, Eric
Pamer, Eric G.
Schluter, Jonas http://orcid.org/0000-0002-6214-9367
Xavier, Joao B. http://orcid.org/0000-0003-3592-1689
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01 AI124275, R01 AI137269, U54 CA209975)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 12 October 2020
Accepted: 12 February 2021
First Online: 2 March 2021
Change Date: 23 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41597-021-00903-0
Competing interests
: M.R.M.v.d.B. and J.U.P. received financial support from Seres Therapeutics. M.-A.P/ has received honoraria from AbbVie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda; has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec; and serves on data and safety monitoring boards for Servier and Medigene and scientific advisory boards for MolMed and NexImmune.